Thalidomide

• UNSPSC Description:

  Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ∼250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties. Thalidomide can work as molecular glue to potentiate substrate.

• Target Antigen:

  Apoptosis; Autophagy; Ligands for E3 Ligase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;PROTAC

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/thalidomide.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1N(C2CCC(NC2=O)=O)C(C3=CC=CC=C31)=O

• Molecular Weight:

  258.233

• References & Citations:

  [1]Fischer ES, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014 Aug 7;512(7512):49-53.|[2]Sun X, et al. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. Med Sci Monit. 2018 May 15;24:3193-3203.|[3]Bian C, et al. Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner. Free Radic Biol Med. 2018 Dec;129:446-453.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  50-35-1